Oramed Pharmaceuticals (ORMP) Cost of Revenue (2016 - 2025)

Oramed Pharmaceuticals has reported Cost of Revenue for 6 years, with the latest figure at $2.0 million in Q1 2025.

• For the quarter ending Q1 2025, Cost of Revenue changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (changed N/A YoY), and the FY2025 full-year result was $2.0 million, changed N/A from the prior year.
• Cost of Revenue for Q1 2025 stood at $2.0 million, up from $663000.0 in the prior quarter.
• The five-year high for Cost of Revenue was $2.0 million in Q1 2025, with the low at $184000.0 in Q1 2023.
• Historically, Cost of Revenue has averaged $637000.0 across 3 years, with a median of $463000.0 in 2022.
• The largest YoY upside for Cost of Revenue was 43.2% in 2023 against a maximum downside of 68.81% in 2023.
• Oramed Pharmaceuticals' Cost of Revenue stood at $463000.0 in 2022, then surged by 43.2% to $663000.0 in 2023, then surged by 199.7% to $2.0 million in 2025.
• The last three Cost of Revenue figures came in at $2.0 million (Q1 2025), $663000.0 (Q3 2023), and $192000.0 (Q2 2023), per Business Quant data.